Pages that link to "Q35586781"
Jump to navigation
Jump to search
The following pages link to Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes (Q35586781):
Displaying 11 items.
- Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer (Q28268250) (← links)
- Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling (Q31132241) (← links)
- Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials (Q33735001) (← links)
- Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations (Q35753798) (← links)
- Clinical use of aromatase inhibitors (AI) in premenopausal women (Q36185862) (← links)
- Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer (Q36993383) (← links)
- Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial (Q37135224) (← links)
- Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG). (Q48247756) (← links)
- Early breast cancer (Q57142283) (← links)
- Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II) (Q57579916) (← links)
- Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer (Q57579999) (← links)